Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background Upper extremity deep vein thrombosis (UEDVT) constitutes around 10% of all
DVT, and can cause both pulmonary embolism (PE) and postthrombotic syndrome (PTS) in …

Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in
persons older than 55 years is at least 33.5 million globally and is predicted to more than …

Background Anti-thrombotic reduces thromboembolic events but increases bleeding in
patients with atrial fibrillation (AF). We evaluated the benefit–risk of anti-platelet and anti …

Background—Sex-specific comparative effectiveness of direct oral anticoagulants among
patients with nonvalvular atrial fibrillation is not known. Via this retrospective cohort study …

BACKGROUND: The clinical trial ARISTOTLE showed that apixaban was superior to
warfarin in reducing the risks of stroke and bleeding among patients with nonvalvular atrial …

Objectives: Compare costs and healthcare resource utilization (HCRU) among newly-
diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs …

Abstract Treatment of venous thromboembolism (VTE) has been confined to parenteral
agents and oral vitamin K antagonists for decades; however, with the approval of the direct …

In this study, all-cause, stroke/systemic embolism (SE)-related, and major bleeding (MB)-
related health-care costs among elderly patients with nonvalvular atrial fibrillation (NVAF) …

Aim Resources devoted to health care are limited, therefore setting priorities is required. It
differs between countries whether decision-making concerning health care technologies …